Range Financial Group LLC Acquires 7,868 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Range Financial Group LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 285.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,626 shares of the biopharmaceutical company’s stock after buying an additional 7,868 shares during the period. Range Financial Group LLC’s holdings in Gilead Sciences were worth $982,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Bellevue Group AG grew its position in Gilead Sciences by 18.2% during the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock valued at $3,859,000 after purchasing an additional 7,093 shares during the last quarter. Quantinno Capital Management LP increased its position in shares of Gilead Sciences by 149.5% during the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock valued at $6,843,000 after acquiring an additional 48,910 shares in the last quarter. Legal & General Group Plc raised its holdings in Gilead Sciences by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after acquiring an additional 93,068 shares during the last quarter. IRON Financial LLC bought a new position in Gilead Sciences in the 3rd quarter valued at approximately $830,000. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in Gilead Sciences by 12.9% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 323,011 shares of the biopharmaceutical company’s stock valued at $27,081,000 after purchasing an additional 36,895 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 8,500 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $91.96, for a total transaction of $781,660.00. Following the sale, the chief financial officer now owns 132,373 shares in the company, valued at approximately $12,173,021.08. This represents a 6.03 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now directly owns 99,599 shares of the company’s stock, valued at $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 453,734 shares of company stock valued at $41,902,086 over the last 90 days. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Price Performance

GILD traded down $0.60 during trading on Tuesday, hitting $90.63. 5,810,275 shares of the company traded hands, compared to its average volume of 5,050,562. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company has a market cap of $112.95 billion, a PE ratio of 1,007.00, a P/E/G ratio of 2.24 and a beta of 0.18. The stock’s 50-day simple moving average is $91.86 and its two-hundred day simple moving average is $82.84. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the business posted $2.29 earnings per share. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.40%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Maxim Group cut Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Citigroup initiated coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $125.00 target price for the company. Wolfe Research started coverage on Gilead Sciences in a report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price objective for the company. Royal Bank of Canada reissued a “sector perform” rating and issued a $84.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Finally, JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Twelve analysts have rated the stock with a hold rating, twelve have assigned a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $96.43.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.